Bleeding Risk in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Systematic Review and Meta‐Analysis. Issue 3 (13th May 2013)

• Record Type: Journal Article
• Authors: Lopes, L C; Spencer, F A; Neumann, I; Ventresca, M; Ebrahim, S; Zhou, Q; Bhatnaga, N; Schulman, S; Eikelboom, J; Guyatt, G
• Is Part Of: Clinical pharmacology & therapeutics. Volume 94:Issue 3(2013)
• Page Start: 367
• Page End: 375
• Publication Date: 2013-05-13
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1038/clpt.2013.99
• Languages: English
• ISSNs: 0009-9236

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Vitamin K antagonists (VKAs) prevent stroke in atrial fibrillation (AF) at the cost of bleeding risk. To determine major bleeding rates in AF patients, we conducted a systematic review that identified 51 eligible studies including more than 342, 699 patients. The pooled estimate of the rate of major bleeding was 2.51 (99% confidence interval: 2.03–3.11) bleeds per 100 patient‐years. The results represent the best estimates of bleeding risk that most patients contemplating VKA use may expect.</p> <p> <italic>Clinical Pharmacology &amp; Therapeutics</italic> (2013); <bold>94</bold> 3, 367–375. doi:<ext-link ext-link-type="doi" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink">10.1038/clpt.2013.99</ext-link></p> </abstract>